NeoGenomics, Inc. (NASDAQ:NEO) Expected to Earn Q1 2020 Earnings of $0.05 Per Share
NeoGenomics, Inc. (NASDAQ:NEO) – Stock analysts at William Blair issued their Q1 2020 EPS estimates for NeoGenomics in a research note issued on Tuesday, October 29th. William Blair analyst B. Weinstein forecasts that the medical research company will earn $0.05 per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for NeoGenomics’ Q2 2020 earnings at $0.07 EPS, Q3 2020 earnings at $0.07 EPS, Q4 2020 earnings at $0.07 EPS and FY2020 earnings at $0.25 EPS.
A number of other research analysts have also commented on NEO. Zacks Investment Research lowered NeoGenomics from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine lowered NeoGenomics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Friday. Needham & Company LLC raised their price target on NeoGenomics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Benchmark set a $27.00 price target on NeoGenomics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. NeoGenomics currently has an average rating of “Buy” and a consensus price target of $24.86.
NEO traded down $0.25 during mid-day trading on Friday, reaching $22.68. The stock had a trading volume of 664,800 shares, compared to its average volume of 1,004,602. The stock has a market capitalization of $2.43 billion, a P/E ratio of 174.46 and a beta of 0.92. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.52 and a current ratio of 4.24. The firm’s fifty day simple moving average is $20.50 and its two-hundred day simple moving average is $22.43. NeoGenomics has a 52 week low of $11.05 and a 52 week high of $26.89.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 29th. The medical research company reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.01. The firm had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The business’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period last year, the company earned $0.05 EPS.
In related news, Director Steven C. Jones sold 1,691 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $25.00, for a total transaction of $42,275.00. Following the sale, the director now owns 245,234 shares of the company’s stock, valued at approximately $6,130,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven C. Jones sold 40,737 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $25.02, for a total value of $1,019,239.74. Following the sale, the director now directly owns 245,234 shares in the company, valued at approximately $6,135,754.68. The disclosure for this sale can be found here. Insiders sold a total of 241,370 shares of company stock worth $6,017,680 over the last 90 days. 8.80% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. NEXT Financial Group Inc raised its stake in shares of NeoGenomics by 200.0% in the 2nd quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 1,800 shares during the period. Captrust Financial Advisors acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at about $66,000. Nisa Investment Advisors LLC raised its stake in shares of NeoGenomics by 867.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 3,470 shares during the period. Winslow Evans & Crocker Inc. acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at about $92,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of NeoGenomics by 14.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 739 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Further Reading: What is Put Option Volume?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source